Is This ADC the Chemo Killer TNBC Needed?

Dato-DXd nears US approval for first-line metastatic TNBC, backed by a landmark 5-month survival gain over chemotherapy

7 May 2026

For patients with metastatic triple-negative breast cancer who can't receive immunotherapy, the treatment menu has long been brutally short: chemotherapy, and not much else. That may be changing. The FDA has granted Priority Review to datopotamab deruxtecan, an antibody-drug conjugate developed by AstraZeneca and Daiichi Sankyo, with regulatory clearance possible as early as Q2 2026.

The case for approval rests on TROPION-Breast02, a global Phase 3 trial enrolling patients with no prior systemic therapy in the advanced setting. The results were striking. Against physician's choice of chemotherapy, Dato-DXd delivered median overall survival of 23.7 months versus 18.7 months. The risk of death fell by 21%; the risk of progression or death dropped by 43%. No other drug has posted a statistically significant survival advantage over chemotherapy in this specific, immunotherapy-ineligible, first-line population.

How it works matters. Dato-DXd targets TROP2, a protein widely overexpressed in TNBC tumors, using a cleavable linker to release a topoisomerase I inhibitor directly inside cancer cells. Precision delivery is the point, sparing healthy tissue while concentrating firepower at the tumor.

Regulators won't wave this through uncritically. Interstitial lung disease, a known risk across DXd-based ADCs, appeared in the trial and will demand close post-approval monitoring. Open questions also linger around how outcomes hold up across patients with varying TROP2 expression levels, a debate that continues to shape patient selection for this entire drug class.

The application is being reviewed under Project Orbis, a mechanism that runs parallel assessments with international partner regulators to speed patient access across borders. Daiichi Sankyo handles manufacturing; AstraZeneca leads global commercialization.

For a population that has waited too long for something better, an approval would represent a genuine reset in standard of care. Precision oncology is redrawing the map for TNBC, and Dato-DXd is at the front of the line.